SPECT Trends in Patients With CAD
been assessed previously. In this study, we analyze trends of SPECT utilization in patients with documented CAD to determine whether they show similar trends in SPECT results.
Methods

Database
The Mayo Clinic, Rochester, nuclear cardiology laboratory maintains an electronic database of all patients undergoing stress SPECT. Stored data include patient demographics, CAD risk factors, and previous CAD history. CAD history was defined as having documented myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) as used previously by the Cedars-Sinai group and in our previous SPECT trends report in patients without CAD. 9, 10 Hypertension is defined as being on antihypertensive therapy or systolic blood pressure of ≥140 mm Hg and diastolic blood pressure of ≥90 mm Hg. Diabetes mellitus is defined as fasting blood glucose ≥126 mg/dL on ≥2 occasions, hemoglobin A1c ≥6.5%, or treatment with insulin/oral diabetes mellitus medications. Dyslipidemia is defined as having a total cholesterol of >250 mg/dL or being on lipid-lowering therapy. Recorded symptoms at the time of SPECT include chest pain and dyspnea. Chest pain is further categorized as typical angina, atypical angina, or noncardiac chest pain according to the criteria of Diamond. 11 For patients with both chest pain and dyspnea, chest pain is considered the primary symptom.
All patients who underwent stress SPECT utilizing technetium Tc 99m sestamibi between January 1, 1991, and December 31, 2012, were included in this study. This database has been used in previous publications from our laboratory. 9, 12, 13 The database includes both inpatient and outpatient SPECT tests performed at Mayo Clinic, Rochester. Analyzed data include all variables with a <1% rate of missing data in each of the possible answers. This study was approved by the Mayo Clinic Institutional Review Board. No extramural funding was used to support this study.
Exclusion Criteria
Patients without a history of established CAD (previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting) before SPECT were excluded. Patients with the following conditions were also excluded: left bundle branch block, paced rhythm, cardiomyopathy, or valvular heart disease. SPECT tests performed with bicycle-exercise/rest-only or with technically inadequate images were excluded. After applying these exclusion criteria, there were 29 886 SPECT tests. For patients with multiple SPECT tests, only the first test was used for analysis, leaving a total of 19 891 unique patients. In accordance with Minnesota state law, patients who did not grant research authorization were excluded (n=518), resulting in a final study cohort of 19 373 patients. There were 9995 repeat SPECT studies of which 255 did not provide research authorization. A total of 9740 repeat SPECT studies were assessed separately.
SPECT Methods
SPECT methodology from our laboratory has been described previously. 9, 14, 15 In brief, patients underwent either symptom-limited treadmill exercise stress (Bruce, modified Bruce, or Naughton protocol) or pharmacological stress (utilizing adenosine, regadenoson, dipyridamole, or dobutamine). A positive stress ECG for ischemia was defined as ≥1.0 mm horizontal or downsloping ST-segment depression 80 ms after the J point compared with baseline. All SPECT studies were interpreted by consensus of a radiologist and a nuclear cardiologist. Image scoring was performed using a 16-segment short-axis model. Each segment was scored as follows: 4=absent uptake, 3=severely decreased uptake, 2=moderately decreased uptake, 1=mildly decreased uptake, and 0=normal uptake. The summed rest score was calculated by addition of the scores for each of the 16 segments using the resting images. The summed stress score (SSS) was calculated using the post-stress images. The summed difference score (SDS) was calculated by subtracting summed rest score from SSS. SSS results were categorized into 3 groups: 0 to 3 (low risk), 4 to 8 (intermediate risk), and ≥9 (high risk).
There were few changes in our nuclear cardiology laboratory personnel or technology used over the study period. Camera equipment and analysis software were the same until early 2010 when the laboratory installed D-SPECT cameras (Spectrum Dynamics).
Test Substitution
To assess for test substitution, we evaluated all stress echocardiograms performed at Mayo Clinic, Rochester, between 2000 and 2012, using an established echocardiography database. 16 We also assessed stress ECG studies performed between 2006 and 2012. The same exclusion criteria used for SPECT were applied to the stress echocardiogram and stress ECG tests, yielding a total of 12 783 stress echocardiograms performed in 2000 to 2012 and 3751 stress ECG tests performed between 2006 and 2012. Given overall small numbers of positron emission tomography (PET) stress tests, we did not apply any of the exclusion criteria but assessed utilization in all of the 2834 PET stress tests performed between 2006 and 2012.
Statistical Analysis
Continuous data are summarized as mean±SD. Categorical data are summarized as frequency and group percentage. The study cohort was divided into 5 
Results
A total of 19 373 patients with established history of CAD were assessed. Mean age was 66.2±10.9 years and 75.4% were men. Baseline characteristics of the study groups are shown in Table 1 . There was a marked increase in the utilization of SPECT in patients with CAD between 1991 and 2000 where annual utilization increased from an average of 495 tests per year in the 1991 to 1995 period up to 1400 studies performed in 2000 (Figure 1 ). There was a plateau in SPECT utilization between 2001 and 2003 followed by marked and progressive decrease in utilization that continued through 2012. In 2012, 552 SPECT studies were performed which was 60.6% lower than the utilization in 2000 (n=1400) and was similar to utilization between 1991 and 1995 (average of 495 tests per year).
Using the same inclusion and exclusion criteria used for SPECT tests, utilization of stress echocardiography and stress ECG declined over time. Data are presented as number (%) or mean±SD. BMI indicates body mass index; and CAD, coronary artery disease. SPECT test results are summarized in Figure 4) . In asymptomatic patients, low-risk tests comprised 25.6% in 1991 versus 78.1% in 2012 (P<0.001 by Fisher exact test). Similarly, low-risk tests increased significantly over time in symptomatic patients from 30% in 1991 to 76.5% in 2012 (P<0.001 by Fisher exact test). These observed trends were also evident regardless of stress modality (pharmacological versus exercise, Figure 5 ).
We also assessed SPECT trends from a CAD diagnosis standpoint in 3 subgroups: (1) MI alone without revascularization, (2) MI with PCI or CABG, and (3) PCI or CABG without history of MI (Table 3 (Table II in the Data Supplement) . Table 4 demonstrates trends of SPECT risk categories over time stratified by modality of stress and stress ECG results. Among patients with exercise SPECT and negative stress ECG, high-risk results decreased significantly parallel to the overall observed trends in our study from 32.6% of these patients in [1991] [1992] [1993] [1994] [1995] Among repeated SPECT studies (n=9,740), similar trends of SSS, low-risk tests, time difference to SPECT, and percentage of patients with history of revascularization without MI were observed compared with the main study cohort (Table III in Data are given as number (%) or mean±SD. CABG indicates coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; and SSS, summed stress score.
*The first line within each subgroup represents the overall number of patients within that subgroup and the percentage compared with the overall number of patients in the corresponding time period.
†The other lines within the subgroups represent number and percentage compared with the overall number within the same subgroup. 
Discussion
SPECT utilization in patients with CAD at our institution increased significantly in the 1990s in a similar fashion to US trends. 17 However, SPECT growth plateaued between 2000 and 2003 followed by a strong trend toward reduced utilization. In 2012, SPECT utilization in patients with CAD was similar to that in the first study period of 1991-1995. The prevalence of CAD risk factors such as hypertension, dyslipidemia, and diabetes mellitus increased while smoking decreased. The increased prevalence of hypertension and dyslipidemia over time likely reflects increased recognition and treatment of these conditions. Testing in asymptomatic patients increased until 2006, but then decreased significantly and was similar in 2011-2012 compared with 1991-1995. Atypical angina and dyspnea increased over time, whereas typical angina decreased.
More importantly, despite having a documented history of CAD, SSS and SDS both decreased significantly over time. Low-risk stress tests increased over time and accounted for 77.1% in 2011-2012 compared with only 27.8% in 1991-1995. Intermediate-and high-risk tests decreased significantly. Interestingly, these trends persisted despite reduced utilization in the 2011 to 2012 period. Regardless of SPECT stress modality (exercise versus pharmacological) or patients' symptomatic status, these trends were evident. When the study group was divided into 3 subgroups on the basis of CAD diagnosis (MI without revascularization, MI with revascularization, and revascularization without MI), the percentage of patients who had MI without revascularization decreased. The percentage of patients who had coronary revascularization without MI increased. The decline in asymptomatic patients after 2006 was seen in all 3 subgroups, but was most dramatic in patients with revascularization (with or without MI). SSS decreased and low-risk stress tests increased in all 3 subgroups. To the best of our knowledge, our study is the first to demonstrate a reduced prevalence of abnormal SPECT studies in patients with an established history CAD similar to what was reported previously in patients without a history of CAD. 8, 9 We have also assessed repeat SPECT studies separately and demonstrated similar overall trends to the main study cohort. After 2001, the majority of repeated tests were performed >2 years after MI, PCI, or CABG, which would probably make them of uncertain appropriateness or appropriate. SPECT testing has the most robust risk stratification and prognostication data among cardiac stress testing modalities. Repeat SPECT testing probably reflects the ordering physicians' desire for better risk stratification for their patients with CAD although repeat testing may not necessarily be appropriate.
In our study, SPECT utilization increased between 1991 and 2000, similar to national trends. 6 SPECT utilization started decreasing nationally in 2006. 6, 7 It is reasonable to 3 Changes in Medicare reimbursement, radiology benefits management programs, and radiation exposure concerns probably also contributed to the observed decline in national utilization. 18, 19 Decreased utilization at our institution seems to have started in 2004, 2 years before national trends and publication of appropriate use criteria. Although the exact causes of this earlier decrease are unclear, they likely reflect continuous quality improvement and efforts by the nuclear cardiology laboratory at our institution to promote the use of treadmill ECG stress testing. 20, 21 The timing of decreased utilization in patients with CAD appears similar to what we have reported previously in patients without a previous history of CAD. 9 Test substitution was also examined in our current study as a possible cause for decreased SPECT utilization. We have demonstrated previously that in patients without a history of CAD, utilization of stress echocardiography and treadmill stress testing has declined over time, arguing against test substitution. 9 In this study, we demonstrated similar findings showing declining utilization of stress echocardiography, stress PET, and stress ECG testing. Our findings suggest that test substitution is unlikely to be a major factor in decreasing SPECT utilization. Similarly, McNulty et al 7 have demonstrated decreased utilization of SPECT at Kaiser Permanente in Northern California without any evidence for test substitution with stress echocardiography or coronary computed tomography.
Trends of SPECT results in patients with an established history of CAD have not been described previously. Two previous studies assessed trends in patients without a previous history of CAD, and both demonstrated a progressive decline of SSS over time with fewer intermediate-or high-risk tests and significantly more low-risk tests. 8, 9 In these 2 studies, the observed trends of decreased SSS and more frequent low-risk tests were consistent despite some differences between the 2 studies such as geographic location, patients' characteristics, and presenting symptomatic status. In another study by McNulty et al, 7 SPECT utilization in patients with and without previous CAD was assessed but they did not report SPECT results or SSS risk categories. However, they demonstrated a significant decline in incident myocardial infarction and coronary artery revascularization after SPECT between 2000 and 2011, which may reflect a decline in high-risk SSS, similar to what we reported previously in patients without a history of CAD 9 and what we are reporting in this study in patients with CAD.
The gradually increasing prevalence of low-risk SPECT stress tests over time indicates milder CAD (assessed by SSS) and less inducible ischemia (assessed by SDS). The causes of this observation are likely multifactorial. Physicians at our institution may have referred less sick patients for SPECT testing although the trends in hypertension, diabetes mellitus, and dyslipidemia increased over time. The increased proportion of patients with history of CABG or PCI without MI would support the notion of less sick patients. Treatment of hypertension and dyslipidemia has improved dramatically over the past 20 years, both nationally and within Minnesota. 22, 23 Although the prevalence of hypertension and dyslipidemia increased in our study over time, this likely corresponds to increased treatment and compliance with guideline-directed medical therapy over the past 10 years. 24 Smoking rates have also decreased over time. 25 Declining national CAD mortality between 1980 and 2000 has been attributed to favorable risk factors at the population level, improved primary prevention (in patients without CAD), and better secondary prevention in patients with established CAD. 26 It has also been shown from the nuclear arm in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) that optimal medical therapy results in improved myocardial perfusion; SSS decreased in the optimal medical therapy arm from 14.7±11 at baseline to 11.4±10 (P<0.01) after 6 to 18 months. 27 Similarly, statins have been shown to reduce SSS by SPECT 28 and also improve myocardial blood flow by PET. 29 Management of patients presenting with a myocardial infarction has also improved over the past 20 years with increasing adherence to guideline-directed medical therapy. 30, 31 Another possible contributor to increased low-risk tests is increasing frequency of complete revascularization with multi-vessel PCI and CABG.
Study Limitations
Our study was based on SPECT studies performed at a tertiary academic medical center, which makes it subject to referral bias. Additional community-based studies are needed to confirm these findings in patients with a history of CAD. Our definition of CAD on the basis of a history of myocardial infarction or coronary revascularization excluded patients without such history but with moderate coronary atherosclerosis found on coronary angiography (such as in the work-up of pre-transplantation patients) if these patients later underwent SPECT stress testing. Major limitations of our study include inability to assess appropriateness of SPECT tests, downstream coronary angiography/revascularization, medical therapy, or cardiovascular outcomes, which warrant further research in the future. Medication data were incomplete in the database to permit reliable analysis. The specialty of the ordering physician was not available for analysis, and patient-specific preferences could not be examined. Finally, assessment of coronary angiography trends as a possible cause for reduced SPECT utilization was not feasible. However, national trends in Medicare beneficiaries suggest declining rates of coronary angiography and PCI since 2006.
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Conclusion
SPECT utilization in patients with a documented history of CAD increased between 1991 and 2000 but later decreased. Utilization in 2012 was similar to utilization between 1991 and 1995. More SPECT tests were low risk regardless of presenting symptoms, stress modality, or the diagnostic subgroup of CAD. SSS, SDS, and positive stress ECG all decreased despite reduced SPECT utilization. Our results suggest that among patients with a history of CAD, SPECT was being increasingly utilized in patients with milder CAD. This trend parallels reduced utilization of stress ECG, stress echocardiography, and coronary angiography, reduced smoking, and greater utilization of medical therapy including statins for SPECT Trends in Patients With CAD prevention and treatment of coronary heart disease, as well as reductions of CAD events nationally.
